AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NASDAQ Stocks In The News.(B)
Byline: David Saito-Chung
Activision has had a superb 2001, rising as much as 161% since pulling out of a yearlong base in the first week of the year. The stock notched a high of 41.15 in June, then settled into its current 11-week base. It's 12% off its peak.
The developer, publisher and distributor of game software announced last week that it is teaming up with Id Software to publish two new games, including Quake IV. Battle game Quake II, which features only the single-player mode, is one of the hottest-selling PC games ever, officials said.
Activision's earnings record has been anything but steady over the past six quarters. But on a long-term basis, earnings per share have grown from 23 cents in fiscal 1998 to 75 cents in fiscal 2001 ended in March. Analysts polled by First Call see earnings rising 16% to 87 cents a share.
...- Taro Receives FDA Approvals for Ciclopirox Topical Solution, 8% (Nail Lacquer)...
- Press release article from: Business Wire September 20, 2007 700+ words
...and its Supplemental ANDA for Loratadine Syrup (Oral Suspension), 5 mg/5 mL ("loratadine syrup") in a grape flavored formulation...approximately $88 million. Taro's loratadine syrup is bioequivalent to Schering's...
- Taro Receives Tentative Approval for Loratadine Syrup.
- Press release article from: Business Wire June 27, 2002 700+ words
...Abbreviated New Drug Application (ANDA) for Loratadine Syrup 10 mg/10 mL. Taro's Loratadine Syrup 10 mg/10 mL is a generic version of...industry sources, the annual market for Loratadine Syrup is estimated to be approximately $70...
- Ranbaxy Receives FDA Approval to Manufacture and Market Loratadine Syrup.
- Press release article from: PR Newswire August 23, 2004 700+ words
...announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Loratadine Syrup (Loratadine Oral Solution, USP), 5 mg/5 mL that is available to patients as an OTC product. The Office of Generic...
- Taro Announces Filing of ANDA for Generic Claritin Syrup; Company Challenges...
- Press release article from: Business Wire August 3, 2001 700+ words
...Food and Drug Administration (FDA) for Loratadine Syrup, a generic equivalent of Schering Corporation...Claritin(R) Syrup. ANDA Application for Loratadine Syrup Loratadine Syrup is an allergy medication used in the nasal...
- Perrigo Company Announces Approvals to Market Three New Products.
- Press release article from: PR Newswire November 14, 2003 700+ words
...Children's Motrin(R) Cold) 2. Loratadine Syrup, 5 mg (Children's Claritin(R...brand are approximately $30 million. Loratadine Syrup Through an agreement with Teva Pharmaceutical...manufacture, market and distribute Loratadine Syrup, 5 mg/5 mL. Teva has received...
- Schering-Plough Announces Claritin(R) Syrup Receives U.S. Marketing Approval...
- Press release article from: PR Newswire December 7, 2000 700+ words
...today announced that CLARITIN(R) (loratadine) Syrup 10 mg/10mL has received marketing...the safety of 5 mg (one teaspoon) loratadine syrup in children ages 2 to 5 years. A...tolerability of 5 mg (one teaspoon) of loratadine syrup after multiple doses. Loratadine...
- Perrigo Company Reports Second Quarter Fiscal 2005 Earnings.
- Press release article from: PR Newswire February 1, 2005 700+ words
...announced expense of the November 2004 retail-level recall of loratadine syrup and the lower than anticipated sales of cough and cold...decline reflected a $6.3 million sales adjustment for the loratadine syrup recall and lower sales in cough/cold and analgesic product...
- Perrigo Company Reports Fiscal 2005 Third Quarter and Nine Months Losses Due to...
- Press release article from: PR Newswire May 5, 2005 700+ words
...charges and expenses associated with the acquisition were the same as those recorded in the third quarter. The impact of the loratadine syrup product recall in the second quarter of fiscal 2005 reduced sales by $6.3 million and after-tax income by $5.3...